DaVita (DVA)
(Delayed Data from NYSE)
$133.51 USD
+0.74 (0.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $133.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVA 133.51 +0.74(0.56%)
Will DVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVA
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
DVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
Is Trending Stock DaVita Inc. (DVA) a Buy Now?
Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing
Other News for DVA
Doctors perform first combined heart pump and pig kidney transplant surgery
DaVita Reaches Analyst Target Price
DaVita's Global Operations Powered by 100% Renewable Energy
Goldman picks top capex and R&D stocks
DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call